PATIENTS IN SCOTLAND GAIN ACCESS TO CANCER TREATMENTS FOR LUNG CANCER AND CHRONIC LYMPHOCYTIC LEUKAEMIA FOLLOWING SMC DECISIONS

Contributed by: AstraZeneca

Tags

cancer

oncology

More Like This

FIRST NICE RECOMMENDED TARGETED TREATMENT OPTION FOR ELIGIBLE PATIENTS LIVING WITH UNRESECTABLE LOCALLY ADVANCED STAGE III EGFR-MUTATED LUNG CANCER

ASTRAZENECA RECEIVES TWO POSITIVE NICE RECOMMENDATIONS FOR LUNG CANCER PATIENTS ACROSS ENGLAND AND WALES

Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023

PR Newswire associated0

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Merus Announces Publication of Abstracts on MCLA-129 for Presentation at ESMO Asia Congress 2023

BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors

Merus Presents Interim Data on MCLA-129 at ESMO Asia Congress 2023

IMFINZI (DURVALUMAB) IN COMBINATION WITH CHEMOTHERAPY RECEIVES POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE FOR PATIENTS WITH RESECTABLE NON-SMALL CELL LUNG CANCER